EAGLE PHARMACEUTICALS INC. overview

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options PR Newswire NEW YORK, Feb. 9, 2024 If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson...

Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX PR Newswire NEW YORK, Feb. 9, 2024 NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eagle Pharmaceuticals, Inc.. Shareholders who purchased shares of EGRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead...

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Feb. 8, 2024 LOS ANGELES , Feb. 8, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX ). Class Period: August 8, 2023 – November 28, 2023 Lead Plaintiff Deadline:...

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024 PR Newswire NEW YORK, Feb. 8, 2024 NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Attention Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals") (NASDAQ: EGRX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 8, 2023 and November 28, 2023 . If you suffered a loss on...

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX PR Newswire NEW YORK, Feb. 7, 2024 NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by...

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Feb. 6, 2024 LOS ANGELES , Feb. 6, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX ). Class Period: August 8, 2023 – November 28, 2023 Lead Plaintiff Deadline:...

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Feb. 6, 2024 NEW YORK , Feb. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Eagle Pharmaceuticals investors who were adversely...

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX PR Newswire NEW YORK, Feb. 3, 2024 NEW YORK , Feb. 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August 8, 2023 and November 28, 2023 , both dates inclusive (the "Class Period"), of the...